The Spanish laboratory Kymos will perform the bioanalysis of the ivermectin-albendazole coformulation

STOP is approaching the launch of its clinical trial, which will test whether a coformulation of ivermectin and albendazole is more effective than albendazole alone in treating soil-transmitted helminths in children.

However, before the phase 3 trial is launched, a phase 2-3 trial is needed to analyse the half-life of both drugs in blood. “We have decided to entrust Kymos with this task, which is not without challenges given that the samples will be collected in Kenya and need to be transported to Spain,” says project leader Jose Muñoz.

“To prevent an interruption of the cold chain during sample collection it was necessary to employ a special technology which calls for expert analytical method development, and I am proud to say that we have succeeded in supporting STOP in the best possible way” says Carles Celma, scientific director at Kymos.  “The opportunity to help combat worm infections and break the cycle of poverty makes this collaboration truly exceptional,” he adds.

 KYMOS is a GLP/GMP-certified, GCP-compliant, EMA and FDA-inspected European contract research organization specialized in bioanalysis and CMC.